The Addition of Intravenous Metronidazole to Oral Vancomycin is Associated with Improved Mortality in Critically Ill Patients with Clostridium difficile Infection

Clinical Infectious Diseases

Volumn 61, Issue 6, 2015, Pages 934-941

  Rokas, Kristina E E ^a   Johnson, James W ^a   Beardsley, James R ^a   Ohl, Christopher A ^b   Luther, Vera P ^b   Williamson, John C ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Clostridium difficile infection; metronidazole; mortality; sepsis; vancomycin

Indexed keywords

METRONIDAZOLE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL EVALUATION; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CRITICALLY ILL PATIENT; FEMALE; HUMAN; INTENSIVE CARE UNIT; KIDNEY DISEASE; LABORATORY TEST; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT DURATION; AGED; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CRITICAL ILLNESS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADULT; AGED; ANTI-INFECTIVE AGENTS; CLOSTRIDIUM DIFFICILE; CRITICAL ILLNESS; DRUG THERAPY, COMBINATION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84940676182     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ409     Document Type: Article

References (21)

1. Hall AJ, Curns AT, McDonald LC, Parashar UD, Lopman BA. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin Infect Dis 2012; 55: 216-23.
2. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multiinstitutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-9.
3. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by the hypervirulent strain in Quebec. CMAJ 2005; 173:1037-42.
4. Dubberke ER, Reske KA, Butler AM, et al. Attributable outcomes of Clostridium difficile-associated disease in non-surgical patients. Emerg Infect Dis 2008; 14:1031-8.
5. O'Brien JA, Lahue BJ, Caro JJ, et al. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007; 28:1219-27.
6. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-55.
7. Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011; 53:440-7.
8. McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007; 28:140-5.
9. Debast SB, Bauer MP, Kuijper EJ, et al. European society of clinical microbiology and infectious diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20:1-26.
10. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27:1169-72.
11. Friedenberg F, Fernandez A, Kaul V, Niami P, Levine GM. Intravenous metronidazole for the treatment of Clostridium difficile colitis. Dis Colon Rectum 2001; 44:1176-80.
12. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficileassociated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-7.
13. Fernandez A, Anand G, Friedenberg F. Factors associated with failure of metronidazole in Clostridium difficile-associated disease. J Clin Gastroenterol 2004; 38:414-8.
14. Walk ST, Micic D, Jain R, et al. Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis 2012; 55:1661-8.
15. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580-637.
16. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108:478-98.
17. Fekety R, Silva J, Kauffman C, Buggy B, Deery HG. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989; 86:15-9.
18. Chung P. Comparing the effectiveness of two oral vancomycin regimens for Clostridium difficile infection [Session 28, Paper K-335]. In: Program and abstracts of the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Denver)
19. Lam SW, Bass SN, Neuner EA, Bauer SR. Effect of vancomycin dose on treatment outcomes in severe Clostridium difficile infection. Int J Antimicrob Agents 2013; 42:553-8.
20. Keighley MR, Burdon DW, Arabi Y, et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhea. Br Med J 1978; 2:1667-9.
21. Gonzales M, Pepin J, Frost EH, et al. Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect Dis 2010; 10:363.